Literature DB >> 6119103

Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension.

R G Wilcox, J R Hampton.   

Abstract

Twenty-five patients with moderate essential hypertension (standing diastolic blood pressure 100-125 mmHg, phase 5) completed a single-blind placebo-controlled cross-over study comparing four week periods of treatment with atenolol 100 mg, metoprolol 100 mg, metoprolol durules 200 mg, slow-release oxprenolol 160 mg, and slow-release oxprenolol 320 mg respectively. All the drugs were significantly better than placebo at reducing resting blood pressure at 24 hours. Atenolol produced the greatest mean reduction of pressure and was the most effective drug for most patients, though the differences between atenolol and metoprolol durules were not statistically significant. These two drugs, however, were significantly more effective than the remainder. A similar ranking was seen with respect to the reduction of the blood pressure and heart rate response to exercise. None of the treatments had any significant effect on the patients' rating of perceived exertion during the exercise test.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6119103      PMCID: PMC482685          DOI: 10.1136/hrt.46.5.498

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  14 in total

1.  Metoprolol or atenolol for mild-to-moderate hypertension.

Authors:  O Lyngstam; L Rydén
Journal:  Lancet       Date:  1979-09-22       Impact factor: 79.321

2.  Perceived exertion as an indicator of somatic stress.

Authors:  G Borg
Journal:  Scand J Rehabil Med       Date:  1970

3.  Dosing intervals in beta blocker therapy.

Authors:  J Erikssen; R Mundal; E Thaulow; S Nitter-Hauge
Journal:  Lancet       Date:  1981-01-03       Impact factor: 79.321

4.  The effect on blood pressure of beta-adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased.

Authors:  M Wilson; G Morgan; T Morgan
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

5.  A new approach to drug trials in general practice. Comparison of the antihypertensive efficacy of metoprolol and atenolol.

Authors:  B J Adams-Strump; J Hayes; J H Barber
Journal:  Practitioner       Date:  1980-05

6.  A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.

Authors:  M J Kendall; V A John; C P Quarterman; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

7.  Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.

Authors:  W J Leahey; J D Neill; M P Varma; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

8.  The effect of beta-adrenoceptor blockade on factors affecting exercise tolerance in normal man.

Authors:  S B Pearson; D C Banks; J M Patrick
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

9.  Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.

Authors:  H C Brown; S G Carruthers; G D Johnston; J G Kelly; J McAinsh; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

10.  Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension.

Authors:  J C Petrie; T A Jeffers; O J Robb; A K Scott; J Webster
Journal:  Br Med J       Date:  1980-06-28
View more
  14 in total

Review 1.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

2.  Effect of controlled-release metoprolol on blood pressure and exercise heart rate in hypertension: a comparison with conventional tablets.

Authors:  L Rydén; B E Kristensson; G Westergren
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  The effects of acute or chronic ingestion of propranolol or metoprolol on the physiological responses to prolonged, submaximal exercise in hypertensive men.

Authors:  R G Wilcox; T Bennett; I A Macdonald; M Herbert; A M Skene
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

4.  Working ability and exercise tolerance during treatment of mild hypertension. II. A comparison between atenolol and prazosin medication.

Authors:  K Lange Andersen; W Ottmann; W Piatkowski; K A Green
Journal:  Int Arch Occup Environ Health       Date:  1985       Impact factor: 3.015

5.  Working ability and exercise tolerance during treatment of a mild hypertension. I. Comparison between a beta-adreno-receptor blocking drug and a calcium antagonist.

Authors:  K Lange Andersen; W Piatkowski; K A Green; W Ottmann
Journal:  Int Arch Occup Environ Health       Date:  1985       Impact factor: 3.015

6.  Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

Authors:  R G Wilcox; J R Hampton
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

7.  Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects.

Authors:  S Rössner; L Weiner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Propranolol vs metoprolol vs labetalol: a comparative study in essential hypertension.

Authors:  M M Kubik; J H Coote
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Long acting beta-blockers in the twenty fourth hour.

Authors:  G I Hackett; P Harrison; S Kershaw
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.

Authors:  F B Müller; L F Allsopp; G L Cooper; P Bolli; P Frei; L Glaus; R Ritz; F R Bühler
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.